Nurix Therapeutics (NASDAQ:NRIX) Rating Increased to Hold at Leerink Partnrs

Leerink Partnrs upgraded shares of Nurix Therapeutics (NASDAQ:NRIX) to a hold rating in a research report report published on Monday morning,Zacks.com reports. Leerink Partnrs also issued estimates for Nurix Therapeutics’ Q1 2025 earnings at ($0.89) EPS and Q2 2025 earnings at ($0.93) EPS.

Several other research analysts have also issued reports on NRIX. HC Wainwright increased their target price on Nurix Therapeutics from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. BTIG Research initiated coverage on Nurix Therapeutics in a research note on Tuesday, December 10th. They issued a “buy” rating and a $35.00 price target on the stock. Stifel Nicolaus upped their price target on Nurix Therapeutics from $34.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Needham & Company LLC cut their price target on Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating on the stock in a research note on Wednesday, January 29th. Finally, BMO Capital Markets initiated coverage on Nurix Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $35.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $30.88.

Nurix Therapeutics Stock Performance

Shares of NASDAQ:NRIX opened at $13.66 on Monday. Nurix Therapeutics has a 52-week low of $11.90 and a 52-week high of $29.56. The firm has a market capitalization of $1.04 billion, a P/E ratio of -4.73 and a beta of 2.18. The stock has a 50 day moving average price of $17.33 and a 200-day moving average price of $20.98.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. On average, equities analysts forecast that Nurix Therapeutics will post -2.99 EPS for the current fiscal year.

Insider Transactions at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 5,825 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $14.49, for a total value of $84,404.25. Following the transaction, the chief financial officer now directly owns 33,724 shares in the company, valued at $488,660.76. This trade represents a 14.73 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Gwenn Hansen sold 3,690 shares of the firm’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the completion of the transaction, the insider now owns 55,937 shares in the company, valued at approximately $1,110,349.45. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,326 shares of company stock worth $213,449 in the last ninety days. Insiders own 7.20% of the company’s stock.

Hedge Funds Weigh In On Nurix Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC raised its holdings in Nurix Therapeutics by 1,711.9% in the 4th quarter. FMR LLC now owns 10,634,231 shares of the company’s stock worth $200,349,000 after purchasing an additional 10,047,329 shares during the period. RA Capital Management L.P. bought a new position in Nurix Therapeutics in the 4th quarter worth $25,120,000. Soleus Capital Management L.P. raised its holdings in Nurix Therapeutics by 97.3% in the 4th quarter. Soleus Capital Management L.P. now owns 2,102,833 shares of the company’s stock worth $39,617,000 after purchasing an additional 1,036,999 shares during the period. Point72 Asset Management L.P. bought a new position in Nurix Therapeutics in the 4th quarter worth $16,447,000. Finally, Boxer Capital Management LLC bought a new position in Nurix Therapeutics in the 4th quarter worth $10,608,000.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.